Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2023

Non-small cell lung cancer (NSCLC) treatment options after chemo-immuno failure

Antibody drug conjugates (ADCs)

Date

03 Dec 2023

Session

Non-small cell lung cancer (NSCLC) treatment options after chemo-immuno failure

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Noemi Reguart Aransay

Authors

N. Reguart Aransay

Author affiliations

  • Dept. Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Role of local treatment

Presenter: Shankar Siva

Session: Non-small cell lung cancer (NSCLC) treatment options after chemo-immuno failure

Resources:

Slides

Webcast

Q&A and discussion

Presenter: All Speakers

Session: Non-small cell lung cancer (NSCLC) treatment options after chemo-immuno failure

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.